Grünenthal Press Releases 2008

Aachen, Germany, 05 December, 2008. Today the winners of the 2008 EFIC-Grunenthal Grant have been awarded by the European Federation of Chapters of the International Association for the Study of Pain (EFIC) and the pharmaceutical company Grunenthal. The grant supports young international scientists in carrying out their excellent work in innovative and exploratory clinical and human experimental pain research. A total of 36 young researchers applied for funds totaling € 100,000.

Interview with Hans G. Kress, MD, PhD, Professor and Chair, Medical University of Vienna, Austria

Aachen, Germany, 24 November, 2008. Today the German pain expert Grunenthal GmbH announces that the U.S. Food and Drug Administration (FDA) has approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain for adults 18 years and older.

Aachen, November 19, 2008. As of January 2009, Harald F. Stock, PhD. (40) will lead the Aachen (Germany) based Pharmaceutical Corporation Grünenthal. Currently Harald Stock is responsible for the American Health Care Company Johnson & Johnson's Orthopaedics franchise in Germany.

Aachen, Germany, 18 November, 2008. In an ageing population, there is an increasing need for adequate pain control. Due to changes in metabolism and a greater risk for the development of adverse effects, older patients require different approaches for the management of chronic pain compared to younger people. The availability of transdermal buprenorphine is particularly suitable for the elderly and has been shown to offer advantages in efficacy and tolerability over other opioids.

Aachen, November 11, 2008. The Aachen pharmaceutical company Grünenthal is reorganising its Senior Management. The Supervisory Board has decided to expand the Executive Board to include a CEO (Chief Executive Officer).

Brussels, Belgium / Aachen, Germany, 23 September, 2008. The European Federation of Chapters of the International Association for the Study of Pain (EFIC) and the pharmaceutical company Grunenthal recently announced the winners of the EFIC-Grunenthal Grant 2008. Each year the grant supports young international scientists in carrying out their excellent work in innovative and exploratory clinical and human experimental pain research.

Glasgow, Scotland/Aachen, Germany, 20 August, 2008. New results from phase III clinical studies for the novel centrally acting analgesic tapentadol immediate release tablets (IR) show high efficacy and improved tolerability profile compared to classical opioids for patients with severe pain.

Aachen, Germany, June 19, 2008 – The prevalence of pain in cancer patients with metastatic cancer or advanced stages of the disease has been estimated to exceed 67% of all cases. Despite recent advances, this pain is frequently undertreated and is often debilitating resulting in a reduced quality of life to sufferers. Buprenorphine is a strong opioid that offers several advantages over morphine.

Paris, France/Aachen, Germany, June 13, 2008. Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved gastrointestinal tolerability1 as well as safety2 profile compared to oxycodone HCl IR. The data were presented by the German pharmaceutical company Grunenthal at this year’s Annual Congress of the European League against Rheumatism (EULAR, June 11–14, Paris, France).